Exploitation of lipid metabolism in improving cancer immune checkpoint therapy response KU Leuven
Immune-checkpoint inhibitor therapy (ICI), aimed at enhancing CD8+ T-cell activity against solid tumours, is revolutionising cancer management, providing unprecedented and sustained responses in several cancer types, including melanoma, clear cell renal cell carcinoma and lung cancer. Unfortunately, only a subset of patients benefits from ICI, emphasizing the need for strategies that sensitise tumours to ICI. Here, by analogy with other ...